Oxybin® — Oxybutynin Hydrochloride — 5 mg Tablets / 5 mg per 5 mL Syrup — EIPICO
1- Disclaimer
This information is intended for medical and pharmaceutical education and should not replace the current approved prescribing information, professional clinical judgment, or individualized advice from a physician or pharmacist. Oxybutynin is a prescription medicine, and its benefits and risks depend on the patient's age, diagnosis, comorbidities, concomitant medicines, and dose.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Product formulations, approved indications, dosing instructions, contraindications, packaging, availability, and regulatory status may change. For use in Egypt, the current package leaflet, product pack, manufacturer information, and Egyptian Drug Authority information should be checked whenever product-specific or regulatory information is required.
2- Summary
Oxybin contains oxybutynin hydrochloride, an oral antimuscarinic (anticholinergic) urinary antispasmodic. It reduces involuntary detrusor-muscle contractions and is used mainly for symptoms such as urinary urgency, increased urinary frequency, and urge urinary incontinence associated with idiopathic overactive/unstable bladder or neurogenic detrusor overactivity.
In appropriately selected children older than 5 years, oxybutynin may also be used for urinary symptoms associated with neurogenic or idiopathic detrusor overactivity and, in some product information, for nocturnal enuresis associated with detrusor overactivity when non-drug measures have been unsuccessful.
Oxybutynin does not treat urinary tract infection itself. Its clinically important adverse effects are mainly related to antimuscarinic activity, including dry mouth, constipation, blurred vision, reduced sweating, urinary retention, and central nervous system effects such as somnolence, confusion, or hallucinations.
3- Brand Name
Brand name: Oxybin®
Egyptian pharmaceutical database records identify Oxybin as an EIPICO product containing oxybutynin, with records for:
- Oxybin 5 mg tablets.
- Oxybin syrup containing oxybutynin 5 mg/5 mL.
The Oxybin product information likewise identifies both tablet and syrup formulations.
The EIPICO online product catalogue located during the current review specifically lists Oxybin syrup 5 mg/5 mL. This does not by itself establish that the tablet presentation has been discontinued; therefore, current market availability of Oxybin tablets should be confirmed from EIPICO, the Egyptian Drug Authority, or current pharmacy supply.
4- Category
Pharmacotherapeutic category:
Antimuscarinic / anticholinergic urinary antispasmodic.
ATC classification: G04BD04 — oxybutynin.
Oxybutynin belongs to the medicines used for urinary frequency and incontinence and is a prescription-only medicine in jurisdictions where current regulatory classifications were reviewed.
5- Active Ingredient
Active ingredient: Oxybutynin hydrochloride.
Each Oxybin dosage unit contains:
- Tablet: Oxybutynin hydrochloride 5 mg.
- Syrup: Oxybutynin hydrochloride 5 mg per 5 mL, equivalent to 1 mg/mL.
Oxybutynin is supplied as the hydrochloride salt and produces systemic antimuscarinic activity after oral administration.
6- Pharmaceutical Form & Strength
Oxybin Tablets:
Immediate-release oral tablets containing 5 mg oxybutynin hydrochloride per tablet.
Oxybin Syrup:
Oral syrup containing 5 mg oxybutynin hydrochloride in each 5 mL.
The documented Egyptian presentations include a pack of 20 tablets and a 120 mL syrup bottle.
Egyptian pharmaceutical database records include both presentations; however, the EIPICO online product catalogue located during the current review specifically lists the syrup. Current availability of each presentation should therefore be verified when this information is clinically or commercially important.
Oxybin should not be confused with prolonged-release/extended-release oxybutynin products, which have different dosing schedules and handling instructions.
7- Manufacturer & Marketing Authorization Holder
Manufacturer / company identified with the product:
Egyptian International Pharmaceutical Industries Company (EIPICO).
Egyptian pharmaceutical database records identify EIPICO as the manufacturer of Oxybin.
A separate marketing-authorization-holder designation is not clearly specified in the publicly accessible Oxybin information reviewed. Where the legal MAH identity is required for regulatory purposes, it should therefore be confirmed from the currently marketed Egyptian pack or the relevant Egyptian Drug Authority record rather than inferred.
8- Mechanism of Action
Oxybutynin inhibits the action of acetylcholine at muscarinic receptors in smooth muscle and also has a direct antispasmodic action on bladder detrusor smooth muscle.
The resulting reduction in detrusor activity:
- decreases involuntary bladder contractions;
- increases functional bladder capacity;
- reduces urgency and frequency;
- reduces episodes of urge urinary incontinence.
Oxybutynin is therefore primarily a muscarinic receptor antagonist, with the inhibition of muscarinic-mediated detrusor contraction providing its principal therapeutic effect.
The active metabolite N-desethyloxybutynin also possesses antimuscarinic activity and contributes to both therapeutic and adverse anticholinergic effects.
9- Spectrum of Activity
An antimicrobial “spectrum of activity” is not applicable to oxybutynin because it is neither an antibacterial nor an antifungal or antiparasitic medicine.
Its pharmacological activity is directed mainly toward muscarinic receptor-mediated smooth-muscle activity, particularly in the urinary bladder.
Consequently, Oxybin may improve bladder urgency, frequency, and detrusor overactivity but does not eradicate organisms responsible for urinary tract infections.
10- Pharmacokinetics
After immediate-release oral administration, oxybutynin is rapidly absorbed from the gastrointestinal tract. Current immediate-release product information reports peak plasma concentrations generally within approximately 0.5–1.4 hours.
Oxybutynin undergoes extensive first-pass hepatic and intestinal metabolism. CYP3A4 is an important enzyme involved in its metabolism. Major metabolites include pharmacologically inactive phenylcyclohexylglycolic acid and the pharmacologically active metabolite N-desethyloxybutynin.
Only a very small proportion of an oral dose is excreted unchanged in urine because metabolism is extensive. The immediate-release elimination half-life is approximately 2 hours, although exposure and half-life may be increased in older adults.
Interindividual pharmacokinetic variability is substantial, which is one reason dosing should be individualized according to therapeutic response and anticholinergic tolerability.
11- Indications
Oxybin is used for symptomatic treatment of:
Adults
- Urinary urgency.
- Increased urinary frequency.
- Urge urinary incontinence.
- Unstable/overactive bladder associated with idiopathic detrusor overactivity.
- Neurogenic detrusor overactivity or detrusor hyperreflexia, including that associated with neurological disorders such as multiple sclerosis or spina bifida.
Children older than 5 years
- Urinary urgency, frequency, and urinary incontinence associated with idiopathic or neurogenic detrusor overactivity.
- Nocturnal enuresis associated with detrusor overactivity, in conjunction with non-drug measures, when appropriate treatment without oxybutynin has been unsuccessful.
Oxybutynin should not automatically be used for every case of childhood bedwetting; the indication, underlying cause, and appropriateness of pharmacological treatment should first be established.
12- Administration
Oxybin is administered orally. Immediate-release oxybutynin can generally be taken with or without food. Doses given more than once daily should be spaced appropriately throughout the day.
Adults
According to the documented Oxybin product information, the usual dose is:
5 mg two or three times daily.
If necessary and tolerated, the dose may be increased to:
5 mg four times daily — maximum 20 mg/day.
The lowest effective dose should be used.
Some contemporary immediate-release oxybutynin products use a lower initial dose before titration. Such product-specific regimens should not be assumed to replace the documented Oxybin regimen; dosing should follow the locally approved product information and the patient's clinical requirements.
Elderly and frail patients
A lower starting dose is advisable because exposure and sensitivity to anticholinergic effects may be increased.
The documented Oxybin product information recommends starting at 2.5 mg two to three times daily, followed by individualized titration according to response and tolerability.
Some current immediate-release oxybutynin SmPCs recommend 2.5 mg twice daily, particularly in frail elderly patients, with cautious titration if required. These recommendations relate to the specific products concerned and reinforce the importance of individualized low-dose initiation rather than replacing the locally approved Oxybin instructions.
Children
Oxybutynin is generally not recommended in children younger than 5 years.
For children older than 5 years, the documented Oxybin product information states:
Neurogenic bladder disorders:
The usual dose is 5 mg twice daily. This may be increased to a maximum of 5 mg three times daily to obtain an adequate clinical response, provided that adverse effects are tolerated.
Nocturnal enuresis:
The usual dose is 5 mg two or three times daily, with the last dose given before bedtime.
In children, the maintenance dose may be reached by upward titration from an initial dose of 2.5 mg twice daily.
Some contemporary immediate-release oxybutynin SmPCs use a more conservative initial regimen of 2.5 mg twice daily, followed by selection of the lowest effective dose and age/body-weight-related maximum doses:
- 5–9 years: up to 2.5 mg three times daily.
- 9–12 years: up to 5 mg twice daily.
- Over 12 years: up to 5 mg three times daily.
A maximum total dose of approximately 0.3–0.4 mg/kg/day is specified in those references. These are product-specific contemporary recommendations and should not be presented as the original Oxybin dosing instructions. Pediatric treatment should be individualized according to diagnosis, age, body weight, response, tolerability, specialist advice, and locally approved prescribing information.
Practical administration
Tablets should be swallowed with water.
For syrup, measure each dose with a calibrated oral syringe, medicine spoon, or measuring device. A household teaspoon should not be used because it may not measure 5 mL accurately.
If a dose is missed, do not take two doses together to compensate.
13- Method of Preparation
No reconstitution or dilution is required for the marketed Oxybin tablets or syrup.
Tablets: Ready for oral administration.
Syrup: Ready for oral administration and should be measured accurately using an appropriate medicine-measuring device.
Do not mix, dilute, crush, or otherwise modify the product unless specifically instructed by a physician, pharmacist, or the current package leaflet.
14- Contraindications
Oxybutynin should not be used in patients with hypersensitivity to oxybutynin or any component of the relevant formulation.
Important contraindications described in Oxybin and/or current immediate-release oxybutynin product information include:
- urinary retention or clinically significant bladder outlet obstruction where retention may be precipitated;
- gastrointestinal obstruction or severe gastrointestinal hypomotility, including paralytic ileus or intestinal atony;
- toxic megacolon;
- severe ulcerative colitis where antimuscarinic inhibition of intestinal motility presents a significant risk;
- narrow-angle glaucoma, particularly uncontrolled narrow-angle glaucoma or a shallow anterior chamber;
- myasthenia gravis in product information where it is designated as a contraindication.
The exact regulatory wording of contraindications differs between jurisdictions and oxybutynin products; the locally approved Oxybin prescribing information should therefore remain the definitive product-specific source.
15- Warnings & Precautions
Anticholinergic CNS effects
Oxybutynin can cause somnolence, confusion, agitation, hallucinations, disorientation, and other central anticholinergic effects. Patients should be monitored particularly after starting therapy or increasing the dose. Dose reduction or discontinuation may be necessary if significant CNS effects occur.
Cognitive effects
Older adults are particularly vulnerable to anticholinergic cognitive adverse effects. Current clinical guidance recommends discussing the potential risk of cognitive impairment and dementia associated with antimuscarinic treatment, particularly when long-term therapy is contemplated.
Large observational studies have reported an association between cumulative exposure to certain bladder anticholinergics and dementia. In a large nested case-control study in adults aged 55 years or older, oxybutynin was among the agents most strongly associated with dementia at higher cumulative exposure levels. For oxybutynin, adjusted odds ratios were approximately 1.31 and 1.28 in two higher cumulative-exposure categories evaluated in that study. However, these observational findings establish an association and do not prove that oxybutynin causes dementia; residual confounding and other biases remain possible. Long-term anticholinergic burden should therefore be considered carefully, particularly in older or cognitively vulnerable patients.
Reduced sweating and heat illness
Oxybutynin reduces sweating. Exposure to high environmental temperatures may therefore result in hyperthermia, heat exhaustion, or heat stroke.
Urinary retention
Use cautiously in patients with clinically significant bladder outlet obstruction, prostatic enlargement, impaired bladder emptying, or other risk factors for retention.
Gastrointestinal disease
Because oxybutynin decreases gastrointestinal motility, caution is required in severe constipation, gastrointestinal obstructive disorders, autonomic neuropathy, intestinal atony, gastro-oesophageal reflux disease, and other conditions in which reduced gastrointestinal motility may be harmful.
Cardiovascular and endocrine conditions
Oxybutynin may aggravate tachycardia and should be used cautiously in patients with cardiac arrhythmias, coronary disease, heart failure, hypertension, or hyperthyroidism.
Glaucoma
Acute ocular pain or a sudden reduction in visual acuity requires urgent medical assessment because antimuscarinics can precipitate acute angle-closure glaucoma in susceptible patients.
Angioedema
Potentially life-threatening angioedema involving the face, lips, tongue, pharynx, or larynx has been reported. Oxybutynin should be stopped and urgent medical attention sought if airway involvement or difficulty breathing occurs.
Oral and dental effects
Persistent reduction in saliva production may promote dental caries, periodontal disease, and oral candidiasis. Good oral hygiene and periodic dental assessment are advisable during long-term therapy.
Renal or hepatic impairment
Clinical data defining specific dosage adjustments are limited. Oxybutynin should therefore be used cautiously and titrated clinically in significant hepatic or renal impairment.
16- Drug Interactions
Other anticholinergic medicines:
Concurrent use may increase dry mouth, constipation, blurred vision, urinary retention, somnolence, confusion, and other antimuscarinic adverse effects.
Examples include medicines with clinically relevant anticholinergic properties such as some first-generation antihistamines, tricyclic antidepressants, antipsychotics, antiparkinsonian anticholinergics, atropine-like drugs, and other bladder antimuscarinics.
CYP3A4 inhibitors:
Oxybutynin is metabolized substantially by CYP3A4. Potent inhibitors such as ketoconazole can markedly increase oxybutynin exposure. Itraconazole, clarithromycin, erythromycin, and other CYP3A4 inhibitors may also increase exposure; clinical monitoring and caution are appropriate.
Prokinetic drugs:
Antimuscarinic activity can oppose the gastrointestinal effects of drugs such as metoclopramide and domperidone.
Cholinesterase inhibitors:
Oxybutynin can pharmacodynamically oppose cholinesterase inhibitors used for conditions such as dementia and may increase the risk of worsening cognitive symptoms.
Absorption of other oral medicines:
Reduced gastrointestinal motility may alter absorption of other drugs, which may be particularly important for medicines with a narrow therapeutic index.
Alcohol and sedating substances:
Alcohol can increase oxybutynin-associated drowsiness and impaired alertness.
Patients should inform their physician or pharmacist about prescription medicines, over-the-counter medicines, and herbal products before treatment.
17- Side Effects
Adverse effects are predominantly consequences of antimuscarinic activity.
Common or clinically important effects
- Dry mouth.
- Constipation.
- Nausea.
- Abdominal discomfort or dyspepsia.
- Dizziness.
- Headache.
- Somnolence or fatigue.
- Blurred vision.
- Dry eyes.
- Reduced sweating and dry skin.
- Facial flushing, which may be more prominent in children.
- Palpitations or tachycardia.
- Difficulty urinating or urinary retention.
Dry mouth is among the most frequently reported effects of immediate-release oxybutynin.
Neuropsychiatric effects
Confusion, agitation, disorientation, hallucinations, nightmares, cognitive impairment, and, less commonly, convulsions or psychotic symptoms have been reported.
Ocular effects
Mydriasis, increased intraocular pressure, blurred vision, and acute narrow-angle glaucoma may occur in susceptible individuals.
Hypersensitivity reactions
Rash, urticaria, facial swelling, and angioedema may occur. Angioedema involving the upper airway is potentially life-threatening.
Heat-related adverse effects
Reduced sweating can lead to excessive body temperature and heat stroke, particularly during hot weather.
Patients experiencing severe urinary retention, acute eye pain or sudden visual disturbance, marked confusion, hallucinations, severe overheating with little or no sweating, facial/tongue swelling, or breathing difficulty require prompt medical assessment.
18- Use in Special Populations
Pregnancy
Human pregnancy data remain limited. Oxybutynin is the best studied of the medicines used for urinary frequency and incontinence during pregnancy, but the available evidence is still insufficient to establish complete safety.
Available human data have not demonstrated a clear increase in congenital malformations. A recent retrospective cohort study evaluated 479 pregnancies exposed to overactive-bladder anticholinergic medicines; oxybutynin accounted for approximately 84% of the exposures. Anticholinergic exposure was associated with a higher risk of the study's composite pregnancy-complication outcome, which included preterm birth or low birth weight (RR 1.65, 95% CI 1.40–1.95), while the observed increase in congenital malformations was not statistically significant (RR 1.24, 95% CI 0.85–1.80).
These observational findings do not establish that oxybutynin itself caused the adverse pregnancy outcomes. UKTIS notes that the reported increases in preterm delivery and low birth weight may be related, at least partly, to the underlying maternal condition and require confirmation.
Oxybutynin should therefore be used during pregnancy only when clinically justified after individualized consideration of the expected maternal benefit and potential fetal and pregnancy risks. Urinary incontinence arising as a normal consequence of pregnancy is generally managed without medication; women requiring treatment for a pre-existing bladder disorder should have therapy reviewed by an appropriate clinician.
Breastfeeding
Current UK Specialist Pharmacy Service guidance considers oxybutynin a preferred option for urinary frequency, urgency, and urge incontinence during breastfeeding in mothers of full-term, healthy infants, based principally on its pharmacokinetic characteristics. Recommendations may differ for premature or medically unwell infants.
Direct published evidence during breastfeeding is limited. SPS notes that there is no published evidence demonstrating an effect of oxybutynin on milk production, although anticholinergic medicines could theoretically reduce milk supply, particularly with longer-term treatment. Infant feeding, adequate weight gain, possible anticholinergic effects, and maternal milk production should therefore be monitored when clinically appropriate.
Some individual product labels remain more restrictive regarding breastfeeding, so treatment should follow individualized medical assessment and locally approved product information.
Children
Use in children younger than 5 years is generally not recommended because safety and efficacy have not been adequately established.
Children older than 5 years may be more susceptible to CNS and psychiatric adverse effects and should be monitored carefully.
Elderly patients
Start with a lower dose and titrate cautiously. Older and frail patients may have increased systemic exposure and are particularly susceptible to constipation, urinary retention, blurred vision, falls, confusion, and cognitive adverse effects.
The overall anticholinergic medication burden should be reviewed, especially during long-term therapy.
Hepatic or renal impairment
Specific evidence-based dosage adjustment schedules have not been established for immediate-release oxybutynin. Cautious use and individualized titration are recommended.
19- Storage Conditions
For Oxybin product information:
Tablets:
Store in a dry place at a temperature not exceeding 30°C.
Syrup:
Store at a temperature not exceeding 30°C.
Keep all medicines out of the sight and reach of children.
Keep the product in its original container/package and observe the expiry date and any additional storage instructions printed on the currently marketed pack.
20- Additional Sections
Effects on Driving and Use of Machines
Oxybutynin can cause drowsiness, dizziness, blurred vision, or impaired concentration. Patients affected by these effects should not drive, operate machinery, or perform hazardous activities until they know how the medicine affects them. Alcohol may worsen drowsiness.
Excipients
The documented Oxybin tablet formulation contains lactose monohydrate in addition to excipients such as microcrystalline cellulose, maize starch, sodium starch glycolate, magnesium stearate, and colloidal silicon dioxide.
The documented syrup contains sucrose, sorbitol solution, methyl paraben, sucralose, sodium cyclamate, glycerol, citric acid, sodium citrate, and purified water.
Relevant excipient intolerances, dietary restrictions, or metabolic conditions should therefore be considered.
Overdose
Oxybutynin overdose may produce severe anticholinergic toxicity, including agitation, delirium, hallucinations, dilated pupils, flushing, fever/hyperthermia, tachycardia or arrhythmias, urinary retention, blood-pressure abnormalities, seizures, respiratory failure, paralysis, or coma.
Suspected overdose requires urgent medical assessment. Management is primarily supportive and guided by clinical toxicology principles; activated charcoal may be appropriate in selected cases. Specific antidotal treatment such as physostigmine is reserved for appropriate severe anticholinergic poisoning under experienced medical supervision because it is not suitable for indiscriminate use.
Packaging
Documented Oxybin presentations include:
- Oxybin 5 mg: carton containing 20 tablets.
- Oxybin 5 mg/5 mL syrup: 120 mL bottle.
Egyptian pharmaceutical database records include both presentations. However, because the EIPICO online product catalogue located during the current review specifically lists the syrup, current commercial availability of the tablet presentation should be verified rather than assumed.
21- Frequently Asked Questions (FAQ)
What is Oxybin mainly used for?
It is mainly used to reduce urinary urgency, excessive urinary frequency, and urge urinary incontinence caused by inappropriate or excessive detrusor contractions.
Is Oxybin an antibiotic for urinary tract infections?
No. Oxybutynin does not kill bacteria and does not treat a urinary tract infection. If urinary symptoms are caused by infection, appropriate investigation and antimicrobial treatment may be required.
Can Oxybin be used for childhood bedwetting?
It may be used in selected children older than 5 years when nocturnal enuresis is associated with detrusor overactivity and appropriate non-drug measures or other treatments have not succeeded. It should not be used indiscriminately for all childhood bedwetting.
Can Oxybin be taken with food?
Immediate-release oxybutynin can generally be taken with or without food. It is preferable to follow a consistent dosing schedule and the instructions supplied with the current product.
How quickly does oxybutynin work?
Some improvement may become apparent during the first one to two weeks, but the full clinical effect may require several weeks. Response and tolerability should be reviewed periodically.
Is dry mouth normal with Oxybin?
Yes. Dry mouth is one of the most characteristic antimuscarinic adverse effects. Persistent dry mouth should not simply be ignored because reduced saliva can contribute to dental and oral problems.
Can elderly people take Oxybin?
Yes, when appropriate, but lower initial doses and careful monitoring are generally advisable. Particular attention should be given to constipation, urinary retention, falls, confusion, and cumulative anticholinergic/cognitive burden.
Can Oxybin be used during pregnancy?
Only after individualized medical assessment. Available human data have not demonstrated a clear increase in congenital malformations, but the evidence remains limited. A recent observational study of overactive-bladder anticholinergics, in which oxybutynin represented most exposures, found an association with increased pregnancy complications including preterm birth or low birth weight. This does not establish causality, and the underlying maternal condition may have contributed to the observed association. The potential benefits and risks should therefore be considered individually.
Can Oxybin be used while breastfeeding?
Current specialist breastfeeding guidance considers oxybutynin a preferred antimuscarinic option for urinary disorders in mothers of full-term, healthy infants, with appropriate monitoring. Direct published breastfeeding evidence is limited, so infant feeding, weight gain, possible anticholinergic effects, and maternal milk supply should be considered, particularly during prolonged treatment. Individual product labeling and clinical circumstances should also be taken into account.
What symptoms require urgent medical attention?
Seek urgent assessment for difficulty breathing or swelling of the tongue/throat, inability to urinate, severe confusion or hallucinations, severe overheating with little or no sweating, or sudden eye pain with visual deterioration.
22- References
- Oxybin product information — Egyptian International Pharmaceutical Industries Company (EIPICO): composition, formulations, indications, dosing, contraindications, precautions, excipients, storage, and packaging.
- Egyptian pharmaceutical database information: records for Oxybin 5 mg tablets and Oxybin 5 mg/5 mL syrup manufactured by EIPICO.
- EIPICO Product Catalogue: current online catalogue located during review specifically listing Oxybin syrup, oxybutynin hydrochloride 5 mg/5 mL.
- Oxybutynin Hydrochloride Tablets 5 mg — Summary of Product Characteristics (SmPC), electronic Medicines Compendium: current information on indications, dosing, contraindications, warnings, interactions, adverse reactions, pharmacodynamics, and pharmacokinetics.
- Oxybutynin Hydrochloride immediate-release product information — electronic Medicines Compendium: contemporary elderly and pediatric dosing recommendations, including lower initial doses and age/body-weight-related pediatric maximum doses.
- DailyMed — Oxybutynin Chloride Immediate-Release Tablets: official U.S. labeling covering dosing, CNS effects, angioedema, contraindications, drug interactions, CYP3A4 metabolism, adverse effects, overdose, and pharmacokinetics.
- American Urological Association/SUFU Guideline on Idiopathic Overactive Bladder: recommendations regarding antimuscarinic therapy, adverse-effect counseling, potential cognitive impairment/dementia risk, and caution in susceptible patients.
- UKTIS/BUMPS — Oxybutynin in Pregnancy: contemporary assessment of human pregnancy exposure data and individualized risk-benefit considerations.
- Welk B, McClure JA, McArthur E, Leong Y. The Association of Adverse Pregnancy Outcomes With Overactive Bladder Anticholinergics. Urogynecology. 2025;31(9):849–856: retrospective cohort study evaluating pregnancy complications and congenital malformations after exposure to overactive-bladder anticholinergic medicines.
- NHS Specialist Pharmacy Service — Treating Urinary Disorders During Breastfeeding: updated July 2026 guidance identifying oxybutynin as the preferred option for urinary disorders during breastfeeding in mothers of full-term, healthy infants, with appropriate clinical assessment and monitoring.
- Iyen B, et al. Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study. BMJ Medicine. 2024: large observational study examining cumulative exposure to individual overactive-bladder anticholinergics, including oxybutynin, and incident dementia.
- BMJ Medicine editorial — Overactive bladder drugs and the risk of dementia: interpretation of the available observational evidence, emphasizing that an association between anticholinergic bladder medicines and dementia does not establish causality.
- NHS — Oxybutynin: practical information concerning administration, dosing, onset of benefit, adverse effects, and precautions.